Processa Pharmaceuticals Inc (PCSA)

US · Healthcare · Biotechnology

$1.90+2.70%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.3M

EPS

$-1.19

Market cap

$5.8M

P/E

3.2

Forward P/E

0.0

P/B

2.81

Book value

$-0.11

EPS (TTM)

$0.65

52-week high

$14.25

52-week low

$1.67

50-day MA

$2.23

200-day MA

$2.90

Beta

0.97

Analysts rate Processa Pharmaceuticals Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $25.00.

Insiders

14.82%

Institutions

18.70%

Fund	Stake
Connective Capital Management LLC	3.05%
Stonepine Capital Management Llc	1.97%
Geode Capital Management, LLC	0.89%
Citadel Advisors Llc	0.76%
Vanguard Capital Management, LLC	0.46%
Vanguard Fiduciary Trust Co	0.39%
UBS Group AG	0.09%
Tower Research Capital LLC	0.03%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Processa Pharmaceuticals Inc — free to start.

Data updated 2026-09-18.